Reflex Testing of Free Prostate-Specific Antigen as Effective Health Care Policy by F. Simona et al.
Reflex Testing of Free
Prostate-Specific Antigen
as Effective Health Care
Policy
To the Editor.—We read with interest
the article by Schifman et al1 dealing
with the utilization of measurement of
free prostate-specific antigen (fPSA).
We would like to contribute by re-
porting our experience about the
management of fPSA requests by
using a reflex testing approach and
briefly discuss the status of the analytic
control of this measurement.
Guidelines recommend testing fPSA
to differentiate benign hyperplasia
from prostate cancer only when total
PSA (tPSA) concentrations in serum
range between 4 and 10 lg/L (ng/mL)
(revised after the assay recalibration,
using the World Health Organization
standards, to 3–10 lg/L [ng/mL]).2
Studies have identified the optimal
fPSA/tPSA cutoff as 20%, which ef-
fectively reduces the number of un-
necessary biopsies.3 In 2006, by
auditing fPSA requests in our institu-
tion, we reported that only 16% (352
of 2247) of those requests complied
with this recommendation, with an
economic waste for our health care
system of ~$56,250 USD per year.4
These data supported the activation of
an automatic reflex test allowing fPSA
determination only when tPSA falls
within the recommended concentra-
tion interval and labelling as ‘‘inap-
propriate’’ the fPSA requests in
samples with tPSA out of the recom-
mended limits. This reflex testing was
first introduced for inpatients and 6
years later for outpatients, for whom
the rate of inappropriate requests was
even higher, with a tPSA ordering
associated to fPSA in approximately
44% (2160 of 4871) of cases.
After 12 years, we recently audited
our laboratory data showing that the
fPSA reflex testing works very well in
decreasing the test inappropriateness,
95.9% (1772 of 1848) being the rate of
appropriately measured fPSA. Con-
sidering the last 6-month data, the
distribution of detectable fPSA values
(limit of detection, 0.01 lg/L [ng/mL];
Cobas e801, Roche Diagnostics,
Mannheim, Germany) showed a me-
dian value (25–75th percentiles) of
0.70 (0.54–0.99) lg/L (ng/mL). Re-
garding the quality of measurements,
we resorted to results from external
quality assessment (EQA) to define (1)
the actual state of harmonization of
running fPSA assays at the concentra-
tions mentioned above, and (2)
whether the concentrations of distrib-
uted EQA samples fit with them. Data
from the national Qualimedlab EQA
(www.qualimedlab.it) (2016–2018 ex-
ercises) for the 4 most popular assays
(Abbott Architect, Beckman Coulter
Access/Dx, Roche Modular/Elecsys/
Cobas, and Siemens Advia Centaur)
on overall concentration means of
fPSA ,1 lg/L (ng/mL) showed a
marked positive bias for Beckman
Coulter systems (on average þ25%),
with other assays being characterized
by a negative bias ranging from1.4%
to10%.5 According to these data and
to the recently published specifications
for fPSA bias (11.7%),6 we can
conclude that the harmonization of
fPSA results obtained by the commer-
cially available measuring systems is
acceptable enough, with some excep-
tions. However, we should observe
that in EQA schemes only fewer than
50% (8 of 18 per year) of exercises
account for samples with fPSA con-
centrations below 1 lg/L (ng/mL),
which mirror the distribution of fPSA
concentrations in appropriate orders.
In conclusion, the use of reflex
testing practice for fPSA should be
strongly recommended as health care
policy and implemented to pursue
appropriate ordering and maximize
clinical effectiveness. EQA providers
should, however, pay more attention
to fPSA concentrations of control
materials to better evaluate the clinical
suitability of available assays.
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In Reply.—We appreciate learning
about how the utilization of free
prostate-specific antigen (PSA) is
managed at your facility. It was
interesting to read that only about
16% of free PSA orders met guide-
lines, which was comparable to the
proportion of cases (163 of 790,
20.6%), collectively that met similar
testing criteria, among 28 Q-Probes
participants.1 Use of a reflex testing
protocol in which total PSA is evalu-
ated first as a prerequisite step to
determine if free PSA is performed
was a sound practice, which effectively
eliminated most of the waste from
unnecessary testing. Another potential
benefit derived from reflex free PSA
testing worth noting is prevention of
diagnostic error by reducing risk that
free PSA may be clinically misapplied
if reported when total PSA is outside
the interpretable range.
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